Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study

Kardiologia Polska

Volumn 66, Issue 6, 2008, Pages 642-649

  Banasiak, Waldemar ^a   Wilkins, Arleta ^b   Pociupany, Robert ^b   Ponikowski, Piotr ^a,c  

^a 4 Wojskowy Szpital Kliniczny   (Poland)

^b Servier Polska   (Poland)

^c Wroclaw Medical University Katedra i Klinika Kardiologii   (Poland)

Author keywords

Outpatient care; Pharmacotherapy; Stable coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CILAZAPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVINOLIN; MOLSIDOMINE; NITRIC ACID DERIVATIVE; PERINDOPRIL; QUINAPRIL; SIMVASTATIN; TICLOPIDINE; TRIMETAZIDINE;

AGED; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTPATIENT; POLAND; PROGNOSIS;

EID: 53549122782     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Guidelines of the Prevention Committee of the Polish Cardiac Society. Prevention of coronary heart disease. Kardiol Pol 2000; 53 (supl. I): II-I48.
2. Hordijk-Trion M, Lenzen M, Wijns W, et al; EHS-CR Investigators. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 2006; 27: 671-8.
3. Rosamond W, Flegal K, Friday G, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-171.
4. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
5. Yusuf S, Sleight P, Pogue J, et al; Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
6. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006; 47: 1576-83.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
10. Fox K, Garcia MA, Ardissino D, et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPGGuidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.
11. Pfisterer M, Buser P, Osswald S, et al. Trial of Invasive versus Medical therapy in Elderly patients (TIME) Investigators. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003; 289: 1117-23.
12. Boden WE, O'Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-16.
13. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
14. Daly CA, Clemens F, Sendon JL, et al. Euro Heart Survey Investigators The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005; 26: 1011-22.
15. Anselmino M, Bartnik M, Malmberg K, et al; Euro Heart Survey Investigators. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. Eur J Cardiovasc Prev Rehabil 2007; 14: 28-36.
16. Lenzen MJ, Boersma E, Bertrand ME, et al. European Society of Cardiology. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005; 26: 1169-79.
17. Rużyłło W, Ponikowski P, Wilkins A. Polish Angina Treatment Pattern Programme Investigators. Clinical characteristics and methods of treatment of patients with stable coronary heart disease in the primary care settings - the results of the Polish, Multicentre Angina Treatment Pattern (ATP) study. Int J Clin Pract 2004; 58: 1127-33.
18. Banasiak W, Pociupany R, Wilkins A, et al. Characteristics of patients with coronary artery disease managed on an outpatient basis in the population of Poland. Results of the multicentre RECENT trial. Kardiol Pol 2007; 65: 132-40.
19. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol 1972; 29: 154-63.
20. Murabito JM, Evans JC, Larson MG, et al. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 1993; 88: 2548-55.
21. Braunwald E, Domanski MJ, Fowler SE, et al.; PEACE Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
22. Hemingway H, McCallum A, Shipley M, et al. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 2006; 295: 1404-11.
23. Gibbons RJ, Abrams J, Chatterjee K, et al.; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41: 159-68.
24. Bongard V, Grenier O, Ferriéres J, et al. Drug prescriptions and referral to cardiac rehabilitation after acute coronary events: comparison between men and women in the French PREVENIR Survey. Int J Cardiol 2004; 93: 217-23.
25. De Velasco JA, Cosin J, López Sendón JL, et al. Secondary prevention of myocardial infarction in Spain. The PREVERSE study. Rev Esp Cardiol 1997; 50: 406-15.
26. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42.
27. Główczyńska R, Pietrasik A, Starczewska ME, et al. Prewencja wtórna zdarzeń sercowo-naczyniowych w praktyce lekarza podstawowej opieki zdrowotnej - podgrupa osób z choroba̧ wieńcowa̧. Kardiol Pol 2006; 64 (supl. 3): 210-7.
28. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 2005; 7: 710-21.
29. Rochon PA, Anderson GM, Tu JV, et al. Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. CMAJ 1999; 161 (11): 1403-8.
30. Simpson E, Beck Ch, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145: 438-44.
31. Fox K, Borer JS, Camm AJ, et al. Resting heart Rate in Cardiovascular Disease. J Am Coll Cardiol 2007; 50: 823-30.